MET and cancer: Activation of MET by HGF, and that of ALK by PTN or MK as its ligands, renders cancer more aggressive by activating multiple downstream pathways, including the PI3/AKT and ERK pathway (Hallberg and Palmer, 2013; Duplaquet et al., 2018).